(Q36472432)

14 August 2017

Technology insight: pharmacoproteomics for cancer--promises of patient-tailored medicine using protein microarrays (English)

1 reference

14 August 2017

1 reference

Julia D Wulfkuhle

1

1 reference

14 August 2017

Kirsten H Edmiston

series ordinal

2

1 reference

14 August 2017

Lance A Liotta

series ordinal

3

1 reference

14 August 2017

Emanuel F Petricoin

series ordinal

4

1 reference

14 August 2017

1 May 2006

1 reference

Nature Clinical Practice Oncology

14 August 2017

1 reference

14 August 2017

3

1 reference

14 August 2017

256-268

1 reference

14 August 2017

5

1 reference

Genomics and proteomics in cancer

14 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0485

7 January 2021

From signatures to models: understanding cancer using microarrays

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0485

7 January 2021

Application of DNA microarray technology in determining breast cancer prognosis and therapeutic response

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0485

7 January 2021

Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0485

7 January 2021

Proteomics in translational cancer research: toward an integrated approach

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0485

7 January 2021

Signaling--2000 and beyond

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0485

7 January 2021

Current two-dimensional electrophoresis technology for proteomics

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0485

7 January 2021

Quantitative analysis of complex protein mixtures using isotope-coded affinity tags

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0485

7 January 2021

Automatic identification of proteins with a MALDI-quadrupole ion trap mass spectrometer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0485

7 January 2021

Large-scale analysis of the yeast proteome by multidimensional protein identification technology

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0485

7 January 2021

2D differential in-gel electrophoresis for the identification of esophageal scans cell cancer-specific protein markers

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0485

7 January 2021

Experimental design and analysis of antibody microarrays: applying methods from cDNA arrays

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0485

7 January 2021

Antibody arrays in cancer research

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0485

7 January 2021

Protein biochips: A new and versatile platform technology for molecular medicine

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0485

7 January 2021

Clinical proteomics: personalized molecular medicine

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0485

7 January 2021

Clinical proteomics: translating benchside promise into bedside reality

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0485

7 January 2021

Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0485

7 January 2021

Protein chip technology

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0485

7 January 2021

Protein arrays: the current state-of-the-art

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0485

7 January 2021

UPA, a universal protein array system for quantitative detection of protein-protein, protein-DNA, protein-RNA and protein-ligand interactions

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0485

7 January 2021

Molecular profiling of human cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0485

7 January 2021

Protein microarrays and proteomics

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0485

7 January 2021

Antibody microarray profiling of human prostate cancer sera: antibody screening and identification of potential biomarkers

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0485

7 January 2021

Protein microarrays: meeting analytical challenges for clinical applications.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0485

7 January 2021

Progress in protein and antibody microarray technology

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0485

7 January 2021

Protein microarrays as tools for functional proteomics

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0485

7 January 2021

Dimensionality is the issue: use of photoaptamers in protein microarrays

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0485

7 January 2021

Recent advances of protein microarrays.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0485

7 January 2021

Antigen arrays for antibody profiling

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0485

7 January 2021

Profiling bladder cancer using targeted antibody arrays

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0485

7 January 2021

Signal pathway profiling of prostate cancer using reverse phase protein arrays

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0485

7 January 2021

Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0485

7 January 2021

Signal pathway profiling of ovarian cancer from human tissue specimens using reverse‐phase protein microarrays

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0485

7 January 2021

Proteomic analysis of apoptotic pathways reveals prognostic factors in follicular lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0485

7 January 2021

Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0485

7 January 2021

Laser capture microdissection

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0485

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0485

7 January 2021

Technology insight: Identification of biomarkers with tissue microarray technology

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0485

7 January 2021

Protein microarrays: molecular profiling technologies for clinical specimens

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0485

7 January 2021

Genomic and proteomic technologies for individualisation and improvement of cancer treatment

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0485

7 January 2021

Use of proteomic analysis to monitor responses to biological therapies

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0485

7 January 2021

Proteomics and ovarian cancer: implications for diagnosis and treatment: a critical review of the recent literature

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0485

7 January 2021

Tyrosine kinases as targets for cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0485

7 January 2021

New anticancer agents and therapeutic strategies in development for solid cancers: a clinical perspective

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0485

7 January 2021

Combining EGFR inhibitors with radiation or chemotherapy: will preclinical studies predict clinical results?

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0485

7 January 2021

ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0485

7 January 2021

A mathematical model of combination therapy using the EGFR signaling network

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0485

7 January 2021

Personalised medicine for cancer: from drug development into clinical practice

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0485

7 January 2021

Gastrointestinal stromal tumors: a paradigm for molecularly targeted therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0485

7 January 2021

Towards molecular diagnosis and targeted therapy of lymphoid malignancies

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0485

7 January 2021

ERBB receptors and cancer: the complexity of targeted inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0485

7 January 2021

Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0485

7 January 2021

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0485

7 January 2021

Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0485

7 January 2021

Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0485

7 January 2021

Targeted therapies in breast cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0485

7 January 2021

Factors predicting response to EGFR tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0485

7 January 2021

Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0485

7 January 2021

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0485

7 January 2021

Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0485

7 January 2021

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0485

7 January 2021

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0485

7 January 2021

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0485

7 January 2021

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0485

7 January 2021

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0485

7 January 2021

Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0485

7 January 2021

The preanalytic phase. An important component of laboratory medicine

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0485

7 January 2021

Identifiers

DOI

10.1038/NCPONC0485

1 reference

14 August 2017

1 reference